Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age50+
SponsorUniversity of Alicante

About this trial

The goal of this clinical trial is to learn if a low to moderate load power training program is feasible and effective for improving fitness and quality of life of people with prostate cancer under androgen suppression therapy and bone or lymph node metastasis. The main questions it aims to answer are:

* Does a low to moderate load power training program improve quality of life in people with metastatic prostate cancer under androgen deprivation therapy? * Does a low to moderate load power training program improve power, strength, endurance, and balance in people with metastatic prostate cancer under androgen deprivation therapy?

Researchers will compare the exercise program with routine care to see if power training works to improve common physical side effects of androgen suppression therapy in patients with metastatic prostate cancer.

Participants will:

* Participate in a supervised exercise program twice a week for 6 months or maintain routine care. * Perform fitness tests and questionnaires about quality of life and mental health. * Those who take part in the exercise program will also perform semi-structured in-depth interviews after the end of the program.

Eligibility criteria

Qualifiers

Histopathologically confirmed diagnosis of prostate adenocarcinoma.

Presence of metastases at initial diagnosis (synchronous mHSPC), or

Development of metastatic disease following prior treatment with curative intent (surgery and/or radiotherapy) (metachronous mHSPC).

Evidence of progression to castration-resistant prostate cancer (CRPC).

Disqualifiers

Evidence of visceral metastatic disease.

Current or prior treatment with a triplet regimen that includes chemotherapy.

History of pathological fracture.

Trial design

Treatments tested in this trial

  • Power training group

Treatment groups

66 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Alicante

Lead sponsor

Hospital General Universitario Dr. Balmis de Alicante

Collaborator